Genetic Variation in Coagulation Factors II, V, VII and Fatal MI

• References

• 1 Iacoviello L, Di Castelnuovo A, De Knjiff P, D’Orazio A, Amore C, Arboretti R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
• 2 Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. N Engl J Med 2000; 343: 774-80.
• 3 Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Arterioscler Thromb 1994; 14: 54-9.
• 4 Ruddock V, Meade TW. Factor VII activity and ischaemic heart disease: fatal and non-fatal events. Quart J Med 1994; 87: 403-6.
• 5 Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lalu K, Penttila A, Karhunen PJ. Glycoprotein IIIa P1A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol 1999; 19: 2573-8.
• 6 Iacoviello L, Di Castelnuovo A, D’Orazio A, Donati MB. Cigarette smoking doubles the risk of myocardial infarction in carriers of a protective polymorphism in the blood coagulation factor VII gene. Thromb Haemost 1999; 81: 658.
• 7 Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998; 351: 233-41.